Maximizing Lymph Node Dissection on Fresh and Fixed Lung Cancer Resection Specimens

Study summary

Lung cancer patients undergoing upfront surgery, highly benefit from a systematic lymph node dissection in the mediastinum and in the surgical specimens. The latter is performed by the pathologist. Developing a standardized technique to dissect the lobectomy specimen has the potential of maximizing the retrieval of all N1 stations lymph nodes. The investigators believe that the adoption of such technique will improve lung cancer staging and identify a higher number of patients that qualify for adjuvant therapies.

Ask AI to explain this study

Start here

Key things to know

Main goalDiagnostic

This describes the study’s primary purpose.

What is being studiedSubjects undergoing a lung specimen lymph node dissection and Control group

The study team can explain what participation involves.

Who it may be forLung Cancer · Lymph Node Metastasis

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Mar 5, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Recruiting

The study is currently accepting participants.

What kind of study?Not applicable

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Brigham and Women's Hospital

Study sponsor

Study overview

What this study is about

Purpose: Diagnostic
Study type: Interventional
Phase: Not applicable
Sponsor: Brigham and Women's Hospital
Interventions being studied: Other: Subjects undergoing a lung specimen lymph node dissection; Other: Control group

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Treatment approach

Surgery→

Study topics

After surgery (adjuvant)→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

1. Subjects with a lung nodule or mass who are eligible to undergo a lobectomy. 2. Subject without any metastasis present. 3. Subjects who have peripheral lung nodule location 4. Subjects must be 18 years of age or older.

Reasons someone may not be able to joinExclusion criteria

1. Subjects who received preoperative chemotherapy or radiotherapy. 2. Subjects who have a lung nodule located in a central location. Central tumors are defined by those infiltrating the lobar airway.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Brigham and Womens HospitalBoston, Massachusetts

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 5, 2026. Always confirm current availability with the study team.

View original record ↗